HUP0004363A3 - Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis - Google Patents

Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis

Info

Publication number
HUP0004363A3
HUP0004363A3 HU0004363A HUP0004363A HUP0004363A3 HU P0004363 A3 HUP0004363 A3 HU P0004363A3 HU 0004363 A HU0004363 A HU 0004363A HU P0004363 A HUP0004363 A HU P0004363A HU P0004363 A3 HUP0004363 A3 HU P0004363A3
Authority
HU
Hungary
Prior art keywords
leishmaniasis
treatment
pharmaceutical compositions
compositions containing
solid pharmaceutical
Prior art date
Application number
HU0004363A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HUP0004363A2 publication Critical patent/HUP0004363A2/hu
Publication of HUP0004363A3 publication Critical patent/HUP0004363A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0004363A 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis HUP0004363A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (2)

Publication Number Publication Date
HUP0004363A2 HUP0004363A2 (hu) 2001-04-28
HUP0004363A3 true HUP0004363A3 (en) 2002-12-28

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004363A HUP0004363A3 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis

Country Status (24)

Country Link
US (1) US6544551B1 (hu)
EP (1) EP1051159B1 (hu)
JP (1) JP2002501015A (hu)
KR (1) KR100517399B1 (hu)
CN (1) CN100413492C (hu)
AT (1) ATE215817T1 (hu)
AU (1) AU756805B2 (hu)
BR (1) BR9814772A (hu)
CA (1) CA2318260C (hu)
CZ (1) CZ299229B6 (hu)
DE (1) DE69804865T2 (hu)
DK (1) DK1051159T3 (hu)
ES (1) ES2175663T3 (hu)
HU (1) HUP0004363A3 (hu)
IL (1) IL136196A (hu)
NO (1) NO20003674D0 (hu)
NZ (1) NZ505648A (hu)
PL (1) PL189654B1 (hu)
PT (1) PT1051159E (hu)
SI (1) SI1051159T1 (hu)
SK (1) SK284839B6 (hu)
TR (1) TR200001717T2 (hu)
UA (1) UA68372C2 (hu)
WO (1) WO1999037289A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
PT1545553E (pt) * 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
AU2004269903B2 (en) 2003-09-09 2010-09-02 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
US20140099364A2 (en) 2004-10-08 2014-04-10 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
MX2013005687A (es) 2010-11-22 2013-10-17 Dafra Pharma Res & Dev Bvba Formas de dosificación sólida de oleil fosfocolina.
BR112013033309B1 (pt) 2011-06-24 2022-07-05 Gri Bio, Inc Uso de tazaroteno e método in vitro para inibição de ativação de células nkt tipo i
EP2983709A1 (en) * 2013-04-08 2016-02-17 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
BR112017005362A2 (pt) 2014-09-17 2018-01-23 Steerlife India Private Ltd composição, forma de dosagem sólida oral, processo para preparação de grânulos efervescentes porosos, processador de parafuso duplo, e, grânulos efervescentes porosos.
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
BR112021020389A2 (pt) * 2019-04-12 2021-12-07 Oblita Therapeutics Bvba Formulações de dosagem em comprimidos de oleil fosfocolina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
CA1280369C (en) * 1985-12-04 1991-02-19 Hansjorg Eibl Pharmaceutical with anti-tumor effect
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0419998A3 (en) * 1989-09-27 1991-10-23 Asta Pharma Aktiengesellschaft Use of alkylphosphonic acid derivatives for the treatment of psoriasis
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
BR9814772A (pt) 2000-10-24
WO1999037289A1 (en) 1999-07-29
JP2002501015A (ja) 2002-01-15
AU756805B2 (en) 2003-01-23
AU6212198A (en) 1999-08-09
NO20003674L (no) 2000-07-18
DE69804865D1 (de) 2002-05-16
CZ20002596A3 (cs) 2000-10-11
PL189654B1 (pl) 2005-09-30
UA68372C2 (en) 2004-08-16
US6544551B1 (en) 2003-04-08
NO20003674D0 (no) 2000-07-18
CN100413492C (zh) 2008-08-27
SK9862000A3 (en) 2000-11-07
PL342838A1 (en) 2001-07-16
DE69804865T2 (de) 2002-11-07
DK1051159T3 (da) 2002-08-05
NZ505648A (en) 2002-10-25
SK284839B6 (sk) 2005-12-01
KR20010034311A (ko) 2001-04-25
EP1051159B1 (en) 2002-04-10
CA2318260C (en) 2006-11-21
CZ299229B6 (cs) 2008-05-21
IL136196A0 (en) 2001-05-20
IL136196A (en) 2004-07-25
ATE215817T1 (de) 2002-04-15
ES2175663T3 (es) 2002-11-16
EP1051159A1 (en) 2000-11-15
HUP0004363A2 (hu) 2001-04-28
CN1283111A (zh) 2001-02-07
CA2318260A1 (en) 1999-07-29
TR200001717T2 (tr) 2000-11-21
PT1051159E (pt) 2002-09-30
KR100517399B1 (ko) 2005-09-28
SI1051159T1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
HUP0201376A2 (en) Thiazoloderivatives and pharmaceutical compositions containing them and process for preparation the compounds
HUP0103511A3 (en) Oxazole compounds and pharmaceutical compositions containing them and process for preparation the compounds
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0103256A3 (en) Thiobenzimidazole derivatives and pharmaceutical compositions containing the compounds
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
HUP9901606A2 (en) Pharmaceutical compositions comprising sildenaphil
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
IL206621A0 (en) Caspase inhibitors and pharmaceutical compositions containing the same
HUP0101580A3 (en) Pharmaceutical compositions capable of being gelled
HUP0103707A3 (en) Formulation of stable oxalyplatinum solution
HUP0103507A3 (en) Pharmaceutical compositions comprising 2-quinolones
HUP0004363A3 (en) Solid pharmaceutical compositions containing miltefosine for use in the treatment of leishmaniasis
IL143841A0 (en) Amide compounds and pharmaceutical compositions containing the same
IL136937A0 (en) τ-GLUTAMYL AND β-ASPARTYL CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
PL343627A1 (en) Medicinal compositions
PL338186A1 (en) Beneficial agent compositions containing alpha-hydroxyesters
HUP0104657A3 (en) Imidazole compounds and pharmaceutical compositions containing them
IL137505A0 (en) Pharmaceutical compositions containing tramadol
HUP0200747A2 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IL142534A0 (en) Pharmaceutical compositions containing an antigen-adjuvent
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
GB2331926B (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ZENTARIS GMBH, DE

Free format text: FORMER OWNER(S): ASTA MEDICA AG., DE; ZENTARIS AG, DE; ZENTARIS GMBH, DE

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished